Cvijic Christine Mikail 4
4 · Neurogene Inc. · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
Neurogene (NGNE) President & CFO Christine Cvijic Sells Shares
What Happened
- Christine Mikail Cvijic, President and Chief Financial Officer of Neurogene Inc., reported three open-market sales on March 13, 2026 totaling 4,045 shares for aggregate proceeds of approximately $84,176. These sales were mandatory share-withholdings to cover tax obligations when a restricted stock unit (RSU) partially vested.
Key Details
- Transaction date: March 13, 2026 (Form 4 filed March 17, 2026 — timely).
- Sales (all reported as S = Sale):
- 2,387 shares @ weighted avg $20.42 (range $19.92–$20.87), proceeds ~$48,748. (F2)
- 1,395 shares @ weighted avg $21.25 (range $20.92–$21.91), proceeds ~$29,637. (F4)
- 263 shares @ weighted avg $22.02 (range $21.92–$22.075), proceeds ~$5,791. (F5)
- Total shares sold: 4,045; total proceeds: ~$84,176.
- Holdings reported after the transaction (per footnote F3): includes unvested RSUs — 10,635 RSUs (granted 3/13/2024, vest 3/13/2027), 20,300 RSUs (granted 3/26/2025, vest in equal installments 2026–2028), 22,000 RSUs (granted 2/20/2026, vest in equal installments 2027–2029) — and 19,200 shares held jointly with spouse David Cvijic.
- Notable footnote: F1 states these sales were automatic (no election by the reporting person) to satisfy tax withholding triggered by the RSU vesting.
Context
- These sales were for tax withholding on vested RSUs (routine administrative sales), not discretionary open-market selling by choice; such transactions are common when equity awards vest. They do not necessarily signal executive sentiment about the company. The filing shows the insider remains substantially invested through unvested RSUs and jointly held shares.
Insider Transaction Report
Form 4
Neurogene Inc.NGNE
Cvijic Christine Mikail
President and CFO
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-13$20.42/sh−2,387$48,748→ 107,456 total - Sale
Common Stock
[F1][F4][F3]2026-03-13$21.25/sh−1,395$29,637→ 106,061 total - Sale
Common Stock
[F1][F5][F3]2026-03-13$22.02/sh−263$5,791→ 105,798 total
Footnotes (5)
- [F1]On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.92 to $20.87, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.075, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic|2026-03-17